Pressure BioSciences compares to Agilent Technologies, Inc. (NYSE:A), Life Technologies Corporation (NASDAQ:LIFE) and Thermo Fisher Scientific, Inc. (NYSE:TMO) as they are all leading providers of important sample preparation or analytical mass spectrometry equipment, which is widely used in the analysis of small molecules including proteins, DNA and RNA.
With a long-standing reputation in the life sciences community as a company committed to the advancement of sample preparation and molecular biology research, Pressure Biosciences, Inc. (OTCQB: PBIO) has resurfaced in the last year with an abundance of activity, and investors in the biosciences industry should take note. Selling at .24 cents a share with a market cap of 2.55M and an average volume of 14,363, the company’s stock should be considered, at the very least, a tremendously undervalued investment.
Relying on its patented Pressure Cycling Technology (PCT), the company markets pressure-generating based machines which “use cycles of hydrostatic pressure to control bio-molecular interactions.” According to Pressure Biosciences CEO, Richard T. Schumacher, these machines can safely reach pressure levels several times greater than those found at the deepest levels of any ocean, and PBIO is the first company to ever harness this technology in a laboratory and market it as instruments and consumables. In addition, with their strong portfolio of 24 issued patents, they just may be the only company to do so well into the future.
Based on the success of this powerful technology, as well as grants totaling nearly a million dollars over the course of the past year, in August the company reported a 70% growth in revenue for the second straight quarter. Total revenue reported for date ending June 30th, 2012 was $630,569, an enormous increase from the $371,329 reported for the same period in 2011, with the company also seeing a marked increase in the installation of its PCT Sample Preparation Systems. These PCT Systems are essentially units which utilize the company’s PCT technology to allow scientists ( including forensics specialists like world-famous scientist Dr. Henry Lee) to isolate molecular samples in a laboratory, a process employed by thousands of scientists in a variety of areas, including human cancer and other diseases, soil and plant biology, vaccine development, mass spectrometry, and even counter-bioterror research.
With their 24 issued patents and an already impressive list of customers, that includes Harvard, Stanford, the FBI, the US Dept of Agriculture, Amgen, Thermo Fisher, and agricultural giant Monsanto, PBIO continues to grow at an unprecedented rate for a company in its field.
Perhaps the most exciting area of discovery for consumers of PCT technology, however, is that of forensics. In mid-October, 2012, after extensive studies of PCT technology within the application of forensic DNA analysis, the Harris County Institute of Forensic Sciences in Houston, Texas, as well as the Institute of Applied Genetics at the University of North Texas Health Science Center (UNT) both concluded that PCT can significantly enhance the accuracy of DNA sample results.
According to Dr. Bruce Budowle of the Institute of Applied Genetics at UNT: “We consider our study as a proof of concept that PCT treatment might be a viable method to overcome certain inhibitory effects that can adversely affect DNA testing. Importantly, it appears that PCT can reduce the effects of inhibitors known to be present in some bone samples, resulting in a marked improvement in DNA testing of these often difficult samples.”
Dr. Budowle presented these findings last week at the annual International Symposium on Human Identification in Nashville, TN. Afterwards, Dr. Nate Lawrence, Vice President of PBI’s Sales and Marketing, announced the company’s intention to “accelerate the development of [its] forensics-based instruments and consumables,” and projected that the increased incorporation of PCT technologies into the field of forensics would result in increased revenue for the company in 2013.
The good news is, of course, that the company has already announced other areas that are also expected to increase revenue in 2013. Nothing like having the ability to put multiple eggs in multiple baskets!
After spending years as a research company, Pressure Biosciences, Inc. has stormed into the instruments and consumables market with a force equal to the pressure elicited by its very machines, and has proven both through practice in the field by major companies and via scientific research, that its PCT Platform technology will be a valuable asset to the life sciences industry for years to come.
Shareholders looking for a tried and true investment into a significantly undervalued company run by a guy who has had three prior major successes for a relatively small amount of capital need look no further than PBIO.